



Aleva Neurotherapeutics Raises USD 13 Million in Latest Financing Round

Lausanne, Switzerland, October 3, 2017 – Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson's Disease and Essential Tremor, today announced that it has raised USD 13 million in a Series D financing round. The round was led by Forrestal Capital, a fund with specific experience in neurological devices. Aleva's existing investors have also participated in the round.

The proceeds of the financing will be used to complete the acquisition of a CE Mark for Aleva's proprietary directSTIM™ Directional Deep Brain Stimulation System. The successful results of Aleva's directSTN pilot study were published in *Brain* and strongly suggest the potential of directional stimulation in improving surgical outcomes.

"We would like to thank both our new and existing investors for this significant support towards the registration of our products, designed to deliver improved therapeutic outcomes for Parkinson's patients. We have completed the first closing, but are still accepting additional investments from qualified investors for a limited time," said André Mercanzini PhD, Founder of Aleva.

In August 2017, Aleva and Nuvectra (NASDAQ: NVTR) approved increasing the scope of their Development Agreement, which combines Aleva's innovative directional lead technology with Nuvectra's proprietary neurostimulation platform. In addition, Aleva will continue its supply and manufacturing agreement with Integer (NYSE: ITGR), a strategic investor in Aleva's previous Series C Financing.

Aleva's DBS devices are designed to be more precise and efficient than currently-available DBS approaches, while causing fewer side effects. Based on its proprietary technology, Aleva has developed two novel brain stimulating products with different properties. The first, directSTIM™, is a complete Directional DBS System for long-term therapy in Parkinson's disease and Essential Tremor; the second, spiderSTIM™, is a full solution for intra-surgical placement of DBS electrodes.

The company is a spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL) Microsystems Laboratory of Prof. Philippe Renaud. Aleva Neurotherapeutics has now raised USD 46 million from renowned institutional investors, among them Forrestal Capital, Kinled Holding, BioMedPartners (through its BioMedInvest-II LP Fund), BB Biotech Ventures LP, Kreaxi and Initiative Capital Romandie, as well as from select private investors.

For more information, visit: www.aleva-neuro.com

###



About Nuvectra Corporation

Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE Marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson's Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com

About Integer™

Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch™ Medical, Lake Region Medical™ and Electrochem™. www.integer.net

About Deep Brain Stimulation

Deep brain stimulation (DBS) is approved worldwide for the treatment of Parkinson's disease (PD), essential tremor, dystonia, obsessive-compulsive disorder (OCD) and epilepsy. It is also under investigation for the treatment of a number of other conditions, including major depression. DBS is a therapy that relies on the delivery of mild electrical pulses to specific areas in the brain via an implanted lead connected to a battery-powered pulse generator placed in the patient's upper chest area. A physician is able to vary and control the stimulation delivered through the lead to the brain using an external, hand-held programmer. At present, DBS systems use leads with electrodes that send out electrical current in all directions, which can result in unwanted side effects.

Contact:

Aleva Neurotherapeutics
André Mercanzini, PhD
Founder
andre.mercanzini@aleva-neuro.com

Media Inquiries:

Richard Kenyon
+44 7831 569940
richardkenyon44@hotmail.com